UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________ FORM 10-Q _________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________to_________ Commission File Number: 001-39949 _________________ Hyperfine, Inc. (Exact name of registrant as spe ...

收入和利润（同比环比） - 公司2025年第二季度每股净投资收益为0.46美元，每股净收入为0.41美元，其中包含一次性加速摊销0.02美元每股[2] - 2025年第二季度投资收入为4300万美元，较上一季度的4210万美元有所增长[8] - 截至2025年6月30日的三个月，公司总投资收入为4.2992亿美元，较2024年同期的4.8951亿美元下降12.2%[17] - 2025年前六个月净投资收入为3.3508亿美元，相比2024年同期的4.5019亿美元下降25.6%[17] - 2025年第二季度利息收入为3.6178亿美元，较2024年同期的4.1973亿美元下降13.8%[17] - 2025年第二季度每股净投资收入为0.46美元，较2024年同期的0.59美元下降22.0%[17] 成本和费用（同比环比） - 公司2025年第二季度总净支出为2610万美元，包括所得税和消费税[9] - 2025年前六个月的总费用为5.0712亿美元，较2024年同期的5.3493亿美元下降5.2%[17] - 2025年第二季度管理费为5089万美元，较2024年同期的5034万美元增长1.1%[17] 股息和股票回购 - 公司宣布第三季度每股基础股息为0.42美元，并支付每股0.05美元的特别股息[3] - 公司授权2000万美元的股票回购计划，将在公开市场以低于每股净资产价值的价格回购普通股[4] 投资组合和资产 - 截至2025年6月30日，公司投资组合公允价值为16.007亿美元，较2024年12月31日的15.989亿美元略有增长[6][7] - 2025年第二季度投资活动包括向3家新投资组合公司投资5750万美元，同时实现9270万美元的退出、销售和还款[7] - 截至2025年6月30日，公司现金及现金等价物为2610万美元，信贷额度未动用额度为2.272亿美元[10] - 公司2025年6月30日的每股净资产价值为19.55美元，较2025年3月31日的19.62美元有所下降[5] - 2025年前六个月净投资活动导致的资产净增（减）为1.8917亿美元，较2024年同期的4.839亿美元下降60.9%[17] - Crescent Capital Group管理的资产规模为470亿美元[19] 债务和资本结构 - 公司债务加权平均成本为6.09%，债务与权益比率为1.23倍[10] 股息收入 - 2025年前六个月来自非控制非关联投资的股息收入为172万美元，较2024年同期的395万美元下降56.5%[17] - 2025年第二季度来自控制投资的股息收入为1600万美元，较2024年同期的2640万美元下降39.4%[17]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-42700 BEST SPAC I ACQUISITION CORP. (Exact Name of Registrant as Specified in Its Charter) British Virgin Islands N/A (State or other jurisd ...

Exhibit 99.1 Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 47% with 32% of patients achieving MMR by 24 weeks and demonstrating a favorable safety and tolerability profile across all dose levels Strong balance sheet with $491 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into the first half of 202 ...

Exhibit 99.1 Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 47% with 32% of patients achieving MMR by 24 weeks and demonstrating a favorable safety and tolerability profile across all dose levels Strong balance sheet with $491 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into the first half of 202 ...

Exhibit 99.1 Aethlon Medical Announces Financial Results for the Fiscal First Quarter Ended June 30, 2025, and Provides Corporate Update Australian Cancer Trial Advances with First Cohort Complete, Amended Protocol, and Promising Preclinical Data Published; Operating Expenses Cut by 32% Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO, August 13, 2025 -- Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and l ...

Exhibit 99.1 Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights Continued advancement of two clinical-stage assets, both with clinically demonstrated single-agent anti- tumor activity -- ACR-368 in a registrational-intent Phase 2 study in endometrial cancer and ACR-2316 in a Phase 1 study in AP3-predicted tumor types New paradigm for accelerated design and development of novel compounds, like ACR-2316, based on optimal intracellular pathway selectivity, uniquely enabl ...

Exhibit 99.1 Hyperion DeFi Provides Corporate Update and Reports Second Quarter 2025 Financial Results Successfully establishes cryptocurrency treasury reserve focused on the HYPE token and becomes the first publicly listed U.S. company to implement DeFi strategies on Hyperliquid blockchain Accumulates more than 1.5 million HYPE to date and establishes co-branded validator with Kinetiq Reiterates FDA registration of the Optejet User Filled Device (UFD) remains on track for September 2025 LAGUNA HILLS, CA—Au ...

Exhibit 99.1 MARPAI REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS Marpai Slashes Losses by Two-Thirds in Q2 2025, Paving the Way to Profitability. Operating Expenses Cut 70% as Turnaround Gains Traction Tampa, August 13, 2025, Marpai, Inc. ("Marpai" or the "Company") (OTCQX: MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services, today announced second quarter 2025 results that mark a decisive step forward in its turnaround strategy. The Company delivered substanti ...

EXHIBIT 99.1 For Immediate Release August 13, 2025 FrontView REIT Announces Second Quarter 2025 Results and Updated Full Year 2025 Guidance Stephen Preston, CEO and Chairman, commented, "We are pleased to report a very successful second quarter driven by strong portfolio execution and prudent capital allocation. We improved key portfolio metrics, increasing occupancy to 97.8%, successfully resolving the vacancy related to the twelve previously reported properties, with nine sold or leased. We acquired appro ...